TIGEN PHARMACEUTICALS

Basic Information

UNIVERSITY OF KENTUCKY
ASTECC BLDG, RM 346
LEXINGTON, KY, 40506

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Long Circulating Liposomal Camptothecins CAP and EAP

    Amount: $0.00

    DESCRIPTION (provided by applicant): Based on the extensive data generated during the phase I portion of our studies, there is sufficient and compelling information to support the fur ...

    STTR Phase I 2001 Department of Health and Human Services
  2. Long Circulating Liposomal Camptothecins CAP and EAP

    Amount: $284,000.00

    DESCRIPTION (provided by applicant): Based on the extensive data generated during the phase I portion of our studies, there is sufficient and compelling information to support the fur ...

    STTR Phase II 2001 Department of Health and Human Services
  3. Potent Topoisomerase I Inhibition For Glioma Therapy

    Amount: $133,125.00

    DESCRIPTION (PROVIDED BY APPLICANT): DB-67 is a promising new silatecan (silylcamptothecin) analog that displays superior blood stability relative to the FDA-approved camptothecin ...

    STTR Phase I 2001 Department of Health and Human Services
  4. N/A

    Amount: $100,000.00

    N/A

    STTR Phase I 2000 Department of Health and Human Services
  5. STABLE CAMPTOTHECIN FORMULATIONS FOR CANCER TREATMENT

    Amount: $100,000.00

    N/A

    STTR Phase I 1998 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government